Rigel Pharmaceuticals, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015. Unaudited financial statements; amounts below are in U.S. dollars. Rigel is a clinical-stage drug developer focused on inflammatory and autoimmune diseases, cancer, and muscle disorders.
Business context and pipeline
Key programs included fostamatinib in Phase 3 trials for immune thrombocytopenic purpura (ITP) and newly initiated Phase 2 development for IgA nephropathy (IgAN); R348 in a Phase 2 trial for dry eye associated with ocular graft-versus-host disease; and partnered oncology programs. Rigel had no marketed drug products and relied on collaboration revenue and financing to support development.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / prior date |
|---|---|---|
| Collaboration revenue | $2.178 million | $0 |
| Research and development expense | $15.702 million | $16.869 million |
| General and administrative expense | $4.717 million | $5.516 million |
| Operating loss | $18.241 million | $22.385 million |
| Net loss | $18.193 million; $0.21 per share | $22.303 million; $0.25 per share |
| Operating cash flow | $17.987 million provided | $16.428 million used |
| Cash and cash equivalents | $42.718 million | $15.203 million at Dec. 31, 2014 |
| Short-term investments | $118.437 million | $127.956 million at Dec. 31, 2014 |
| Total cash, cash equivalents and short-term investments | $161.155 million | $143.159 million at Dec. 31, 2014 |
Q1 2015 comprehensive loss was $18.169 million. The filing does not present a meaningful product gross margin; operations were research and development focused. No borrowings or interest-bearing debt are shown on the balance sheet. Current liabilities were $34.349 million, including $19.335 million of current deferred revenue. Total stockholders’ equity was $112.148 million. Contractual facility lease commitments were $44.267 million, before expected sublease income.
Changes versus the comparable period
- Revenue increased from zero, reflecting a new Bristol Myers Squibb (BMS) collaboration. The $30 million upfront payment was received in March and is recognized over the estimated research term through September 2016; $2.1 million was recognized from the upfront payment and $106,000 for research services in Q1. The remaining $27.9 million was deferred at quarter-end.
- Net loss narrowed by approximately $4.1 million. R&D expense decreased $1.167 million, primarily due to lower facilities costs following the sublease and completion or discontinuation of programs, partly offset by increased fostamatinib spending. G&A expense decreased $799,000, mainly due to lower facilities and personnel costs.
- Operating cash flow improved to positive $17.987 million, primarily because of the BMS cash receipt; it should not be read as recurring cash generation. Cash and investments increased by approximately $18.0 million from year-end.
Outlook, commentary and risks
- Management believed existing capital resources would fund current and projected requirements into the second quarter of 2017, but noted that estimates depend on uncertain assumptions. Additional financing may be needed; no future funding other than contingent collaboration and royalty payments was committed.
- Management expected R&D expense to increase through 2015 as the ITP Phase 3 and IgAN and ocular GvHD Phase 2 trials progressed. Expected milestones included ITP top-line results in mid-2016 and an NDA filing by year-end 2016; IgAN results in the second half of 2016; and R348 ocular GvHD results in the second quarter of 2016.
- BMS received exclusive rights and responsibility for clinical development and commercialization of the TGF-beta inhibitor collaboration. Rigel may qualify for development and regulatory payments exceeding $309 million for a successful compound in certain indications, plus tiered royalties and reimbursement for agreed research costs. These contingent payments depend on partner progress and may never be received. The filing cites potential future contingent payments exceeding $453.5 million across current collaborations, also subject to substantial uncertainty.
- Rigel recorded a $9.3 million loss on its December 2014 sublease; it expected more than $12 million in sublease income and operating-cost reimbursements over the remaining term. The sublease liability was $8.586 million at March 31, 2015.
- Principal risks include clinical failure or delays, regulatory uncertainty, future capital needs and potential dilution, dependence on collaborators and third-party manufacturers, intellectual-property challenges, and competition. Rigel reported no legal proceedings and stated that disclosure controls were effective.
Important facts for investors to verify
- Whether the BMS collaboration’s research obligations, revenue recognition and future milestone prospects develop as expected; the upfront payment is not equivalent to recurring revenue.
- Enrollment, timing and results of the fostamatinib ITP Phase 3 trials and the IgAN and ocular GvHD Phase 2 trials, including the stated result and filing timelines.
- Whether the cash runway estimate through Q2 2017 remains realistic as clinical spending increases, and whether additional financing or dilution becomes necessary.
- The terms, collectability and actual net benefit of the office sublease, alongside the remaining facility lease obligations.
- Potential effects of clinical setbacks, collaborator decisions, manufacturing constraints, regulatory requirements and intellectual-property risks on program timelines and funding needs.